Report error Found 51 Enz. Inhib. hit(s) with all data for entry = 50023683
TargetNACHT, LRR and PYD domains-containing protein 3(Human)
A Johnson & Johnson Company
Curated by ChEMBL
A Johnson & Johnson Company
Curated by ChEMBL
Affinity DataIC50: 1.30nMAssay Description:Inhibition of NLRP3 in LPS-induced human PBMC cells assessed as inhibition of IL-1beta secretion pretreated with compound for 30 mins followed by LPS...More data for this Ligand-Target Pair
TargetNACHT, LRR and PYD domains-containing protein 3(Human)
A Johnson & Johnson Company
Curated by ChEMBL
A Johnson & Johnson Company
Curated by ChEMBL
Affinity DataIC50: 1.80nMAssay Description:Inhibition of NLRP3 in LPS-induced human PBMC cells assessed as inhibition of IL-1beta secretion pretreated with compound for 30 mins followed by LPS...More data for this Ligand-Target Pair
TargetNACHT, LRR and PYD domains-containing protein 3(Human)
A Johnson & Johnson Company
Curated by ChEMBL
A Johnson & Johnson Company
Curated by ChEMBL
Affinity DataIC50: 2nMAssay Description:Inhibition of NLRP3 in LPS-induced human PBMC cells assessed as inhibition of IL-1beta secretion pretreated with compound for 30 mins followed by LPS...More data for this Ligand-Target Pair
TargetNACHT, LRR and PYD domains-containing protein 3(Human)
A Johnson & Johnson Company
Curated by ChEMBL
A Johnson & Johnson Company
Curated by ChEMBL
Affinity DataIC50: 2.10nMAssay Description:Inhibition of NLRP3 in LPS-induced human PBMC cells assessed as inhibition of IL-1beta secretion pretreated with compound for 30 mins followed by LPS...More data for this Ligand-Target Pair
TargetNACHT, LRR and PYD domains-containing protein 3(Human)
A Johnson & Johnson Company
Curated by ChEMBL
A Johnson & Johnson Company
Curated by ChEMBL
Affinity DataIC50: 2.60nMAssay Description:Inhibition of NLRP3 in LPS-induced human PBMC cells assessed as inhibition of IL-1beta secretion pretreated with compound for 30 mins followed by LPS...More data for this Ligand-Target Pair
TargetNACHT, LRR and PYD domains-containing protein 3(Human)
A Johnson & Johnson Company
Curated by ChEMBL
A Johnson & Johnson Company
Curated by ChEMBL
Affinity DataIC50: 3.20nMAssay Description:Inhibition of NLRP3 in LPS-induced human PBMC cells assessed as inhibition of IL-1beta secretion pretreated with compound for 30 mins followed by LPS...More data for this Ligand-Target Pair
TargetNACHT, LRR and PYD domains-containing protein 3(Human)
A Johnson & Johnson Company
Curated by ChEMBL
A Johnson & Johnson Company
Curated by ChEMBL
Affinity DataIC50: 3.70nMAssay Description:Inhibition of NLRP3 in LPS-induced human PBMC cells assessed as inhibition of IL-1beta secretion pretreated with compound for 30 mins followed by LPS...More data for this Ligand-Target Pair
TargetNACHT, LRR and PYD domains-containing protein 3(Human)
A Johnson & Johnson Company
Curated by ChEMBL
A Johnson & Johnson Company
Curated by ChEMBL
Affinity DataIC50: 4.5nMAssay Description:Inhibition of NLRP3 in LPS-induced human PBMC cells assessed as inhibition of IL-1beta secretion pretreated with compound for 30 mins followed by LPS...More data for this Ligand-Target Pair
TargetNACHT, LRR and PYD domains-containing protein 3(Human)
A Johnson & Johnson Company
Curated by ChEMBL
A Johnson & Johnson Company
Curated by ChEMBL
Affinity DataIC50: 4.5nMAssay Description:Inhibition of NLRP3 in LPS-induced human PBMC cells assessed as inhibition of IL-1beta secretion pretreated with compound for 30 mins followed by LPS...More data for this Ligand-Target Pair
TargetNACHT, LRR and PYD domains-containing protein 3(Human)
A Johnson & Johnson Company
Curated by ChEMBL
A Johnson & Johnson Company
Curated by ChEMBL
Affinity DataIC50: 5.80nMAssay Description:Inhibition of NLRP3 in LPS-induced human PBMC cells assessed as inhibition of IL-1beta secretion pretreated with compound for 30 mins followed by LPS...More data for this Ligand-Target Pair
TargetNACHT, LRR and PYD domains-containing protein 3(Human)
A Johnson & Johnson Company
Curated by ChEMBL
A Johnson & Johnson Company
Curated by ChEMBL
Affinity DataIC50: 6.30nMAssay Description:Inhibition of NLRP3 in LPS-induced human PBMC cells assessed as inhibition of IL-1beta secretion pretreated with compound for 30 mins followed by LPS...More data for this Ligand-Target Pair
TargetNACHT, LRR and PYD domains-containing protein 3(Human)
A Johnson & Johnson Company
Curated by ChEMBL
A Johnson & Johnson Company
Curated by ChEMBL
Affinity DataIC50: 6.80nMAssay Description:Inhibition of NLRP3 in LPS-induced human PBMC cells assessed as inhibition of IL-1beta secretion pretreated with compound for 30 mins followed by LPS...More data for this Ligand-Target Pair
TargetNACHT, LRR and PYD domains-containing protein 3(Human)
A Johnson & Johnson Company
Curated by ChEMBL
A Johnson & Johnson Company
Curated by ChEMBL
Affinity DataIC50: 6.90nMAssay Description:Inhibition of NLRP3 in LPS-induced human PBMC cells assessed as inhibition of IL-1beta secretion pretreated with compound for 30 mins followed by LPS...More data for this Ligand-Target Pair
TargetNACHT, LRR and PYD domains-containing protein 3(Human)
A Johnson & Johnson Company
Curated by ChEMBL
A Johnson & Johnson Company
Curated by ChEMBL
Affinity DataIC50: 7.90nMAssay Description:Inhibition of NLRP3 in LPS/Nigericin induced human CD14-positive cell assessed as inhibition of caspase-1 level pretreated with compound followed by ...More data for this Ligand-Target Pair
TargetNACHT, LRR and PYD domains-containing protein 3(Human)
A Johnson & Johnson Company
Curated by ChEMBL
A Johnson & Johnson Company
Curated by ChEMBL
Affinity DataIC50: 8.30nMAssay Description:Inhibition of NLRP3 in LPS-induced human PBMC cells assessed as inhibition of IL-1beta secretion pretreated with compound for 30 mins followed by LPS...More data for this Ligand-Target Pair
TargetNACHT, LRR and PYD domains-containing protein 3(Human)
A Johnson & Johnson Company
Curated by ChEMBL
A Johnson & Johnson Company
Curated by ChEMBL
Affinity DataIC50: 8.30nMAssay Description:Inhibition of NLRP3 in LPS-induced human PBMC cells assessed as inhibition of IL-1beta secretion pretreated with compound for 30 mins followed by LPS...More data for this Ligand-Target Pair
TargetNACHT, LRR and PYD domains-containing protein 3(Human)
A Johnson & Johnson Company
Curated by ChEMBL
A Johnson & Johnson Company
Curated by ChEMBL
Affinity DataIC50: 8.70nMAssay Description:Inhibition of NLRP3 in LPS-induced human PBMC cells assessed as inhibition of IL-1beta secretion pretreated with compound for 30 mins followed by LPS...More data for this Ligand-Target Pair
TargetNACHT, LRR and PYD domains-containing protein 3(Human)
A Johnson & Johnson Company
Curated by ChEMBL
A Johnson & Johnson Company
Curated by ChEMBL
Affinity DataIC50: 10nMAssay Description:Inhibition of NLRP3 in LPS-induced human PBMC cells assessed as inhibition of IL-1beta secretion pretreated with compound for 30 mins followed by LPS...More data for this Ligand-Target Pair
TargetNACHT, LRR and PYD domains-containing protein 3(Human)
A Johnson & Johnson Company
Curated by ChEMBL
A Johnson & Johnson Company
Curated by ChEMBL
Affinity DataIC50: 11nMAssay Description:Inhibition of NLRP3 in LPS-induced human PBMC cells assessed as inhibition of IL-1beta secretion pretreated with compound for 30 mins followed by LPS...More data for this Ligand-Target Pair
TargetNACHT, LRR and PYD domains-containing protein 3(Human)
A Johnson & Johnson Company
Curated by ChEMBL
A Johnson & Johnson Company
Curated by ChEMBL
Affinity DataIC50: 13nMAssay Description:Inhibition of NLRP3 in LPS-induced human PBMC cells assessed as inhibition of IL-1beta secretion pretreated with compound for 30 mins followed by LPS...More data for this Ligand-Target Pair
TargetNACHT, LRR and PYD domains-containing protein 3(Human)
A Johnson & Johnson Company
Curated by ChEMBL
A Johnson & Johnson Company
Curated by ChEMBL
Affinity DataIC50: 13nMAssay Description:Inhibition of NLRP3 in LPS-induced human PBMC cells assessed as inhibition of IL-1beta secretion pretreated with compound for 30 mins followed by LPS...More data for this Ligand-Target Pair
TargetNACHT, LRR and PYD domains-containing protein 3(Human)
A Johnson & Johnson Company
Curated by ChEMBL
A Johnson & Johnson Company
Curated by ChEMBL
Affinity DataIC50: 18nMAssay Description:Inhibition of NLRP3 in LPS-induced human PBMC cells assessed as inhibition of IL-1beta secretion pretreated with compound for 30 mins followed by LPS...More data for this Ligand-Target Pair
TargetNACHT, LRR and PYD domains-containing protein 3(Human)
A Johnson & Johnson Company
Curated by ChEMBL
A Johnson & Johnson Company
Curated by ChEMBL
Affinity DataIC50: 22nMAssay Description:Inhibition of NLRP3 in LPS-induced human PBMC cells assessed as inhibition of IL-1beta secretion pretreated with compound for 30 mins followed by LPS...More data for this Ligand-Target Pair
TargetNACHT, LRR and PYD domains-containing protein 3(Human)
A Johnson & Johnson Company
Curated by ChEMBL
A Johnson & Johnson Company
Curated by ChEMBL
Affinity DataIC50: 32nMAssay Description:Inhibition of NLRP3 in LPS-induced human PBMC cells assessed as inhibition of IL-1beta secretion pretreated with compound for 30 mins followed by LPS...More data for this Ligand-Target Pair
TargetNACHT, LRR and PYD domains-containing protein 3(Human)
A Johnson & Johnson Company
Curated by ChEMBL
A Johnson & Johnson Company
Curated by ChEMBL
Affinity DataIC50: 41nMAssay Description:Inhibition of NLRP3 in LPS-induced human PBMC cells assessed as inhibition of IL-1beta secretion pretreated with compound for 30 mins followed by LPS...More data for this Ligand-Target Pair
TargetNACHT, LRR and PYD domains-containing protein 3(Human)
A Johnson & Johnson Company
Curated by ChEMBL
A Johnson & Johnson Company
Curated by ChEMBL
Affinity DataIC50: 43nMAssay Description:Inhibition of LPS-induced NLRP3 in human whole blood pretreated with LPS for 1 hr followed by compound addition and measured after 30 mins by MSD ana...More data for this Ligand-Target Pair
TargetNACHT, LRR and PYD domains-containing protein 3(Human)
A Johnson & Johnson Company
Curated by ChEMBL
A Johnson & Johnson Company
Curated by ChEMBL
Affinity DataIC50: 47nMAssay Description:Inhibition of NLRP3 in LPS-induced human PBMC cells assessed as inhibition of IL-1beta secretion pretreated with compound for 30 mins followed by LPS...More data for this Ligand-Target Pair
TargetNACHT, LRR and PYD domains-containing protein 3(Human)
A Johnson & Johnson Company
Curated by ChEMBL
A Johnson & Johnson Company
Curated by ChEMBL
Affinity DataIC50: 52nMAssay Description:Inhibition of NLRP3 in LPS-induced human PBMC cells assessed as inhibition of IL-1beta secretion pretreated with compound for 30 mins followed by LPS...More data for this Ligand-Target Pair
TargetNACHT, LRR and PYD domains-containing protein 3(Human)
A Johnson & Johnson Company
Curated by ChEMBL
A Johnson & Johnson Company
Curated by ChEMBL
Affinity DataIC50: 68nMAssay Description:Inhibition of LPS-induced NLRP3 in human whole blood pretreated with LPS for 1 hr followed by compound addition and measured after 30 mins by MSD ana...More data for this Ligand-Target Pair
TargetNACHT, LRR and PYD domains-containing protein 3(Human)
A Johnson & Johnson Company
Curated by ChEMBL
A Johnson & Johnson Company
Curated by ChEMBL
Affinity DataIC50: 81nMAssay Description:Inhibition of NLRP3 in LPS-induced human PBMC cells assessed as inhibition of IL-1beta secretion pretreated with compound for 30 mins followed by LPS...More data for this Ligand-Target Pair
TargetNACHT, LRR and PYD domains-containing protein 3(Human)
A Johnson & Johnson Company
Curated by ChEMBL
A Johnson & Johnson Company
Curated by ChEMBL
Affinity DataIC50: 282nMAssay Description:Inhibition of NLRP3 in LPS-induced human PBMC cells assessed as inhibition of IL-1beta secretion pretreated with compound for 30 mins followed by LPS...More data for this Ligand-Target Pair
TargetNACHT, LRR and PYD domains-containing protein 3(Human)
A Johnson & Johnson Company
Curated by ChEMBL
A Johnson & Johnson Company
Curated by ChEMBL
Affinity DataIC50: 320nMAssay Description:Inhibition of NLRP3 ATPase (unknown origin) by ADP-Glo luminescent assayMore data for this Ligand-Target Pair
TargetNACHT, LRR and PYD domains-containing protein 3(Human)
A Johnson & Johnson Company
Curated by ChEMBL
A Johnson & Johnson Company
Curated by ChEMBL
Affinity DataIC50: 534nMAssay Description:Inhibition of NLRP3 in LPS-induced human PBMC cells assessed as inhibition of IL-1beta secretion pretreated with compound for 30 mins followed by LPS...More data for this Ligand-Target Pair
TargetNACHT, LRR and PYD domains-containing protein 3(Human)
A Johnson & Johnson Company
Curated by ChEMBL
A Johnson & Johnson Company
Curated by ChEMBL
Affinity DataIC50: 955nMAssay Description:Inhibition of NLRP3 in LPS-induced human PBMC cells assessed as inhibition of IL-1beta secretion pretreated with compound for 30 mins followed by LPS...More data for this Ligand-Target Pair
TargetNACHT, LRR and PYD domains-containing protein 3(Human)
A Johnson & Johnson Company
Curated by ChEMBL
A Johnson & Johnson Company
Curated by ChEMBL
Affinity DataIC50: 2.46E+3nMAssay Description:Inhibition of NLRP3 in LPS-induced human PBMC cells assessed as inhibition of IL-1beta secretion pretreated with compound for 30 mins followed by LPS...More data for this Ligand-Target Pair
TargetNACHT, LRR and PYD domains-containing protein 3(Human)
A Johnson & Johnson Company
Curated by ChEMBL
A Johnson & Johnson Company
Curated by ChEMBL
Affinity DataIC50: 3.40E+3nMAssay Description:Inhibition of NLRP3 in LPS-induced human PBMC cells assessed as inhibition of TNF-alpha secretion pretreated with compound for 30 mins followed by LP...More data for this Ligand-Target Pair
TargetNACHT, LRR and PYD domains-containing protein 3(Human)
A Johnson & Johnson Company
Curated by ChEMBL
A Johnson & Johnson Company
Curated by ChEMBL
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of NLRP3 in LPS-induced human PBMC cells assessed as inhibition of IL-6 secretion pretreated with compound for 30 mins followed by LPS sti...More data for this Ligand-Target Pair
TargetNACHT, LRR and PYD domains-containing protein 3(Human)
A Johnson & Johnson Company
Curated by ChEMBL
A Johnson & Johnson Company
Curated by ChEMBL
Affinity DataIC50: 2.00E+4nMAssay Description:Inhibition of NLRP3 in LPS-induced human PBMC cells assessed as inhibition of IL-6 secretion pretreated with compound for 30 mins followed by LPS sti...More data for this Ligand-Target Pair
TargetNACHT, LRR and PYD domains-containing protein 3(Human)
A Johnson & Johnson Company
Curated by ChEMBL
A Johnson & Johnson Company
Curated by ChEMBL
Affinity DataIC50: 2.00E+4nMAssay Description:Inhibition of NLRP3 in LPS-induced human PBMC cells assessed as inhibition of IL-6 secretion pretreated with compound for 30 mins followed by LPS sti...More data for this Ligand-Target Pair
TargetNACHT, LRR and PYD domains-containing protein 3(Human)
A Johnson & Johnson Company
Curated by ChEMBL
A Johnson & Johnson Company
Curated by ChEMBL
Affinity DataIC50: 2.00E+4nMAssay Description:Inhibition of NLRP3 in LPS-induced human PBMC cells assessed as inhibition of IL-6 secretion pretreated with compound for 30 mins followed by LPS sti...More data for this Ligand-Target Pair
TargetNACHT, LRR and PYD domains-containing protein 3(Human)
A Johnson & Johnson Company
Curated by ChEMBL
A Johnson & Johnson Company
Curated by ChEMBL
Affinity DataIC50: 2.00E+4nMAssay Description:Inhibition of NLRP3 in LPS-induced human PBMC cells assessed as inhibition of IL-6 secretion pretreated with compound for 30 mins followed by LPS sti...More data for this Ligand-Target Pair
TargetNACHT, LRR and PYD domains-containing protein 3(Human)
A Johnson & Johnson Company
Curated by ChEMBL
A Johnson & Johnson Company
Curated by ChEMBL
Affinity DataIC50: 2.00E+4nMAssay Description:Inhibition of NLRP3 in LPS-induced human PBMC cells assessed as inhibition of TNF-alpha secretion pretreated with compound for 30 mins followed by LP...More data for this Ligand-Target Pair
TargetNACHT, LRR and PYD domains-containing protein 3(Human)
A Johnson & Johnson Company
Curated by ChEMBL
A Johnson & Johnson Company
Curated by ChEMBL
Affinity DataIC50: 2.00E+4nMAssay Description:Inhibition of NLRP3 in LPS-induced human PBMC cells assessed as inhibition of IL-6 secretion pretreated with compound for 30 mins followed by LPS sti...More data for this Ligand-Target Pair
TargetNACHT, LRR and PYD domains-containing protein 3(Human)
A Johnson & Johnson Company
Curated by ChEMBL
A Johnson & Johnson Company
Curated by ChEMBL
Affinity DataIC50: 2.00E+4nMAssay Description:Inhibition of NLRP3 in LPS-induced human PBMC cells assessed as inhibition of IL-6 secretion pretreated with compound for 30 mins followed by LPS sti...More data for this Ligand-Target Pair
TargetNACHT, LRR and PYD domains-containing protein 3(Human)
A Johnson & Johnson Company
Curated by ChEMBL
A Johnson & Johnson Company
Curated by ChEMBL
Affinity DataIC50: 2.00E+4nMAssay Description:Inhibition of NLRP3 in LPS-induced human PBMC cells assessed as inhibition of IL-6 secretion pretreated with compound for 30 mins followed by LPS sti...More data for this Ligand-Target Pair
TargetNACHT, LRR and PYD domains-containing protein 3(Human)
A Johnson & Johnson Company
Curated by ChEMBL
A Johnson & Johnson Company
Curated by ChEMBL
Affinity DataIC50: 2.00E+4nMAssay Description:Inhibition of NLRP3 in LPS-induced human PBMC cells assessed as inhibition of TNF-alpha secretion pretreated with compound for 30 mins followed by LP...More data for this Ligand-Target Pair
TargetNACHT, LRR and PYD domains-containing protein 3(Human)
A Johnson & Johnson Company
Curated by ChEMBL
A Johnson & Johnson Company
Curated by ChEMBL
Affinity DataIC50: 2.00E+4nMAssay Description:Inhibition of NLRP3 in LPS-induced human PBMC cells assessed as inhibition of TNF-alpha secretion pretreated with compound for 30 mins followed by LP...More data for this Ligand-Target Pair
TargetNACHT, LRR and PYD domains-containing protein 3(Human)
A Johnson & Johnson Company
Curated by ChEMBL
A Johnson & Johnson Company
Curated by ChEMBL
Affinity DataIC50: 2.00E+4nMAssay Description:Inhibition of NLRP3 in LPS-induced human PBMC cells assessed as inhibition of TNF-alpha secretion pretreated with compound for 30 mins followed by LP...More data for this Ligand-Target Pair
TargetNACHT, LRR and PYD domains-containing protein 3(Human)
A Johnson & Johnson Company
Curated by ChEMBL
A Johnson & Johnson Company
Curated by ChEMBL
Affinity DataIC50: 2.00E+4nMAssay Description:Inhibition of NLRP3 in LPS-induced human PBMC cells assessed as inhibition of TNF-alpha secretion pretreated with compound for 30 mins followed by LP...More data for this Ligand-Target Pair
TargetNACHT, LRR and PYD domains-containing protein 3(Human)
A Johnson & Johnson Company
Curated by ChEMBL
A Johnson & Johnson Company
Curated by ChEMBL
Affinity DataIC50: 2.00E+4nMAssay Description:Inhibition of NLRP3 in LPS-induced human PBMC cells assessed as inhibition of TNF-alpha secretion pretreated with compound for 30 mins followed by LP...More data for this Ligand-Target Pair






























